The Medicines Co. Pulls European Application For Oritavancin
This article was originally published in The Pink Sheet Daily
Specialty pharma plans to investigate antibiotic as single-dose, 1,200 mg therapy after FDA and EMEA turned down proposed 200 mg, multi-day dosing.
You may also be interested in...
The Medicines Company gradually has revised its business model, moving into earlier-stage research, largely through the acquisition of two biotechs in the past year.
Proposed merger would see The Medicines Company take over development of oritavancin, stalled at FDA due to “complete response” letter.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.